Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001475494 | SCV001679684 | likely benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2021-08-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002499055 | SCV002799498 | likely benign | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2021-12-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003258896 | SCV003947144 | uncertain significance | Inborn genetic diseases | 2023-06-06 | criteria provided, single submitter | clinical testing | The c.1754C>T (p.P585L) alteration is located in exon 9 (coding exon 8) of the CACNA1H gene. This alteration results from a C to T substitution at nucleotide position 1754, causing the proline (P) at amino acid position 585 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV003441982 | SCV004168037 | uncertain significance | not provided | 2023-04-16 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |